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Effects of Chemically Characterized Fractions from Aerial Parts of
Echinacea purpurea and E. angustifolia on Myelopoiesis in Rats
Abstract
Echinacea species are used for beneficial effects on immune function, and various prevalent phytochemicals
have immunomodulatory effects. Using a commercial E. purpurea (L.) Moench product, we have evaluated
the myelopoietic effect on bone marrow of rats treated with various extracts and correlated this with their
chemical class composition. Granulocyte/macrophage-colony forming cells (GM-CFCs) from femurs of
female Sprague-Dawley rats were assessed at 24 h after 7 daily oral treatments. A 75 % ethanolic extract at 50
mg dried weight (derived from 227 mg aerial parts) per kg body weight increased GM-CFCs by 70 % but at
100 mg/kg was without effect. Ethanolic extracts from aerial parts of E. angustifolia DC. var. angustifolia andE.
purpurea from the USDA North Central Regional Plant Introduction Station increased GM-CFCs by 3- and
2-fold, respectively, at 200 mg/kg (∼ 1400 mg/kg plant material). Extract from another USDA E.
angustifoliawas inactive. Proton and APT NMR, MS, and TLC indicated alkylamides and caffeic-acid
derivatives (CADs) present in ethanolic extracts of both the commercial and USDA-derived material.
Cichoric and caftaric acids were prominent in both E. purpurea ethanolic extracts but absent in E. angustifolia.
Aqueous extract of the commercial material exhibited polysaccharide and CAD signatures and was without
effect on GM-CFCs. A methanol-CHCl3 fraction of commercial source, also inactive, was almost exclusively 1
: 4 nonanoic : decanoic acids, which were also abundant in commercial ethanolic extract but absent from
USDA material. In conclusion, we have demonstrated an ethanol-extractable myelostimulatory activity in
Echinacea aerial parts that, when obtained from commercial herbal supplements, may be antagonized by
medium-chain fatty acids presumably derived from a non-plant additive.
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Introduction
!
Echinacea species (Asteraceae) are used as immu-
nomodulants in folk medicine, and their preva-
lent constituent classes – alkylamides, caffeic-acid
derivatives (CADs), and polysaccharides – have
various effects on the immune system [1,2]. Nu-
merous responses to fractions enriched in specific
constituents have been described with mature ef-
fector cells. Innate immune-system phagocytes
yield anti-inflammatory effects with alkylamides
[3–7] and proinflammatory effects with polysac-
charide fractions [8,9]. Alkylamide inhibition of
cyclooxygenase-2 (COX-2) provides another
mechanism for suppression of inflammation
[10]. Anti-inflammatory activity of Echinacea
CADs has been reported [11]. A relatively unex-
plored mechanism for immune enhancement
could entail stimulation of the bone marrow pro-
genitor cells of mature effector cells. Evidence ex-
ists that NK prelymphocytes are increased in fe-
murs of mice consuming a commercial Echinacea
preparation [12,13].
Medicinally important species, E. angustifolia, E.
purpurea, and E. pallida (Nutt.) Nutt., differ quali-
tatively and quantitatively in their phytoconstitu-
ents [1,14,15]. Differential immune effects for the
different species have been correlated with con-
tent of their major constituent classes and princi-
pal compounds. Bioactivity-directed fractiona-
tions coupledwith chemical-constituent profiling
have led to identification of molecular targets for
specific compounds, such as the cannabinoid
type-2 receptor [3,16] and peroxisome prolifera-
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tor-activated receptor-gamma [17,18] as targets of specific alky-
lamides. Evidence implicating these same receptors in hemato-
poiesis [19–22] supports the feasibility of Echinacea immunosti-
mulation through modulation of myelopoiesis.
Inconsistent results have been obtained from clinical studies test-
ing Echinacea for immune enhancement; perhaps the most nota-
ble one relates to the prevention and/or treatment of the com-
mon cold [23]. Relevant procedural differences may include the
use of roots versus aerial parts from specific species or mixtures
of Echinacea species. A dedicated harvest was processed specifi-
cally for one large trial [24], while commercially marketed prod-
ucts were used in others [25]. Some of the latter occasionally con-
tain non-plant additives, such as medium-chain triglycerides
(MCT) [26]. Although the composition was analytically verified
in most studies, active principles mediating a given outcome are
unknown and not necessarily the constituents used for validation
or standardization.
This study assessed Echinacea effects on myelomonocytic precur-
sor cells in assays for granulocyte/macrophage-colony forming
cells (GM-CFCs). We evaluated activity of ethanolic and aqueous
extracts from a commercial preparation of dried aerial parts of E.
purpurea on GM-CFCs from bone marrow of treated rats. Active
ethanolic extract was compared to those from accessions of E. an-
gustifolia and E. purpurea harvested from the USDANorth Central
Regional Plant Introduction Station to insure that bioactivity was
due to plant-derived constituent(s). We used 1H HMR for source
validation since this technique has been used similarly for Echi-
nacea fingerprinting [27,28]. APT NMR and TLC analyses were
used to compare principal constituent classes and relate to
GM‑CFC induction across the various source materials.
Materials and Methods
!
Plant material
Commercial Echinacea was obtained in capsules (Natural Whole
Herb) manufactured by Idea Sphere, Inc. (lots 207079164 and
207438435). Product was labeled as Echinacea purpurea (aerial
part) with gelatin, purified water, and medium-chain triglycer-
ides (MCT). Maximum intake is suggested at 3.42 g/d (~ 50mg/
kg/d for 70 kg body wt). Aerial parts of accessions Echinacea an-
gustifolia DC. var. angustifolia (PI 649026, Minnesota, and PI
649029, North Dakota) and Echinacea purpurea (PI 649040, Ala-
bama), representing source-identified, wild populations, were
obtained from the U.S. Department of Agriculture, North Central
Regional Plant Introduction Station, Ames, IA. Plants were har-
vested July 2007, and dried aerial parts were stored dessicated
at − 20°C until use. Voucher specimens are deposited at ISC as J.
McCoy s.n., 26 Jun 2007 for E. angustifolia PI 649026 and PI
649029 and J. McCoy s.n., 7 Jul 2007 for E. purpurea PI 649040.
Echinacea extraction
Contents of commercial Echinacea capsules were emptied, and
half was macerated with 75% ethanol (0.05 g dry wt/mL; Pharm-
co-AAPER) at room temperature overnight and then again for
6 h. Extracts were combined, evaporated in a rotary evaporator
at 40°C and then lyophilized to give a semisolid residue of 22%
yield (8.7 g/39 g of original powder). The second half was steeped
in distilled water at room temperature and aqueous phase was
strained from solids, washed with 10% (v/v) MeOH (99.9%;
Pharmco-AAPER) in CHCl3 (99.8%; Mallinckrodt), dried under
vacuum and lyophilized to result in a solid of 30% yield. The
MeOH‑CHCl3 (1 :9, v/v) wash of the aqueous phase was retained,
evaporated and lyophilized to yield a pale green liquid (2.6%
yield; hereafter referred to as MeOH‑CHCl3 wash). Dried aerial
parts of E. angustifolia and E. purpurea accessions were pulver-
ized in a blender and extracted with 75% ethanol as described
above. Yields of ethanolic extracts from E. angustifolia PI 649026
and PI 649029 and E. purpurea PI 649040 were 12.7, 11.9, and
15.1% by weight, respectively. Ethanol extracts were analyzed
for endotoxin using Limulus amebocyte lysate with diazo cou-
pling employing a kit from Associates of Cape Cod, Inc. LPS con-
tent was 13 EU/mg, 4 EU/mg, 4 EU/mg, and 9 EU/mg for dried
ethanolic extracts from commercial E. purpurea, PI 649040, PI
649026, and PI649029, respectively. Similar values for dried plant
material yielded extracts that were inactive in a reporter assay for
LPS activation of NF-kB [29]. Specific activity of the kit standard (9
EU/ng) predicts that the highest amount dosed was 0.3 µg/kg,
which is 105-fold less than the rat oral LD50 for endotoxin.
NMR studies
NMR spectra were acquired using a JEOL Eclipse NMR spectrom-
eter operating at 400MHz for 1H and 100MHz for 13C equipped
with a 5-mm gradient proton/multifrequency probe with 2H lock
and z-gradient. Probe temperature was maintained at 25°C. APT
(attached proton test) spectra were acquired using τ = 5 ms and
display of quaternary and methylene carbons up and methyl and
methine carbons down. Chemical shifts are relative to internal
reference tetramethylsilane (TMS, δ = 0.00). Ethanolic extracts
were dissolved in 700 µL DMSO (d6) (99.9%; Cambridge Isotope
Laboratories). Immediately before analysis, MeOH‑CHCl3 wash
was dissolved in CDCl3 and aqueous extract in D2O (both solvents
99.8%; Spectrum).
High-performance thin-layer chromatography
HPTLC of ethanolic fractions and MeOH‑CHCl3 wash was per-
formed using polar and apolar mobile phases to resolve CADs
and alkylamides, respectively [30]. Dried ethanol extract was
sonicated with MeOH (0.1 g/mL) for 5min, then filtered through
a 0.2-µm syringe filter. Samples (5 µL) were chromatographed on
silica gel 60 F254 plates (10 × 20 cm, 0.2mm; E. Merck) with
EtOAc-acetone-formic acid-H2O (15:9:1:1) and stained with di-
phenylborinic acid aminoethylester (Sigma-Aldrich). Caftaric and
cichoric acids and echinacoside standards (10mg/mL; Chroma-
Dex) were cochromatographed. Samples and standard β-sitos-
terol (10mg/mL; ChromaDex) were chromatographed using tol-
uene-EtOAc-cyclohexane-formic acid (24 :6 :3:0.9) mobile phase
and visualized with p-anisaldehyde-sulfuric acid (Sigma-Al-
drich). HPTLC with apolar development was also used for prepar-
ative isolation of bands A and B (l" Fig. 5, Rf = 0.26 and 0.36, resp.)
of E. angustifolia PI 649029 for MS analysis.
MS analysis
Mass spectroscopy was conducted using a 3200 Q-trap LC/MS/
MS system (Applied Biosystems). Software used for controlling
this equipment, acquiring, and processing data was Analyst ver-
sion 1.4.1 software (MDS Sciex). Analytes were ionized using
electro-spray ionization (ESI) interface operated in the positive
mode for alkylamide-enriched samples and negative mode for
fatty acids. Analyses were conducted using Q1 scans with direct
injection of samples in 0.05% formic acid in MeOH into the MS.
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Animal husbandry and treatment
Female Sprague-Dawley (SD) rats (175–240 g) were from the
breeding colony maintained at the University of Louisiana at
Monroe (ULM). Breeders were from Harlan-Sprague Dawley. Rats
had unlimited access to pelleted rodent chow (no. 7001; Harlan/
Teklad) and tap water. Rats were housed under controlled tem-
perature and humidity and a 12-h light/dark cycle. All animal
husbandry and handling conditions were maintained in accor-
dance with the 1996 Guide for Use and Care of Animals of the Na-
tional Research Council. Protocols were preapproved by the ULM
Institutional Animal Care and Use Committee.
Rats were weighed and randomly assigned to treatment. Treat-
ments for commercial preparations were vehicle (5% DMSO in
corn oil), 75% ethanolic (50 and 100mg of dry weight/kg/d) and
aqueous (69mg of dry wt/kg/d) extracts, and MeOH‑CHCl3 wash
(5.9mg of liquid/kg/d). Dosages of 50, 69, and 5.9mg/kg of etha-
nolic, aqueous, andMeOH‑CHCl3 fractions, respectively, provided
equivalence to 230mgof encapsulated startingmaterial/kg. Etha-
nolic extracts of USDA accessions were administered at 50, 100,
and 200mg dry weight/kg/d. All groups of rats (n = 4–6) were
treated once daily for 7 days by oral gavage (10mL/kg). For com-
mercial ethanolic extract, we tested 2 different lots (#207079164
and 207438435). Twenty-four h or 14 d after the last dose, ani-
mals were weighed, then euthanized under CO2 anesthesia, and
femurs were processed for bone marrow cell isolation.
Bone marrow cell isolation
Femurs were dissected from the carcass, cleaned of tissue and re-
moved of ends. Each marrow cavity was flushed with an 18-g
needle with 3mL of filter (0.2 µm)-sterilized Iscoveʼs modified
Dulbecco medium (IMDM) containing 0.2% bovine serum albu-
min and 1% antibiotic/antimycotic (Gibco/BRL). Femurs were in-
verted and flushed againwith the same 3mLmedium. Hereafter,
sterile tissue culture procedures were used. A single-cell suspen-
sion was produced by trituration, filtration through nylon mesh,
and centrifugation (250 × g, 10min). Cells were resuspended in
3mL medium, counted with a hemocytometer and processed for
assay of myeloid lineage colony forming units.
Myeloid lineage colony formation assays (GM-CFCs)
Mononuclear bone marrow cells were isolated by density-gra-
dient centrifugation (400 × g, 30min) over Histopaque-1077
(1.077 g/mL; Sigma-Aldrich). Cells were collected at the interface,
diluted with 10mL medium, pelleted by centrifugation (400 × g,
10min), resuspended in 0.25mL of medium and counted. The
GM‑CFC assay was performed with a HALO kit (cat # K1-GM2;
HemoGenix). In brief, 20000 mononuclear cells in 15 µL IMDM
medium were mixed with 60 µL methyl cellulose, 60 µL fetal calf
serum, and 15 µL growth factor mix (20 ng/mL GM‑CSF, 10 ng/mL
IL-3, and 50 ng/mL SCF, all rat recombinant) and plated per well
in 96-well plates. After 5 days at 37°C in a humidified 5% CO2 in-
cubator, cellular ATP was measured with luciferase and luciferin
substrate and calibrated against a standard curve generated on
the same day. Luminescence was read with a Cameleon II plate
reader (Hidex Ltd.).
Statistical Analysis
!
Effects of Echinacea fractions on myelostimulation were deter-
mined by one-way ANOVA with Dunnettʼs post hoc comparisons
of treatment means against vehicle control done with JMP 4.0
(SAS Institute, Inc.). Two-way ANOVA with Tukey-Kramer post
hoc tests were performed with SAS, v. 9.1 to determine statistical
significance of source and dose on GM-CFCs, bone marrow cellu-
larity, and body weight gain.
Supporting information
Spectra of commercial E. purpurea aqueous extract and effects of
75% ethanolic extract as well as aqueous extract and its
MeOH‑CHCl3 wash from commercial E. purpurea on femur GM-
CFCs are available as Supporting Information.
Results and Discussion
!
Studies presented here describe a myelostimulatory activity of
Echinacea aerial plant parts that is evident when extracted into
75% ethanol. This activity, measured as the number of myeloid
progenitor cells (GM-CFCs) of bone marrow from treated rats,
was originally observed in the extract of a commercial source of
E. purpurea aerial parts formulated with other labeled ingre-
dients. Myelostimulatory activity was also present in ethanolic
extracts of accessions of Echinacea aerial parts from the USDA
North Central Regional Plant Introduction Station and was
present in both E. angustifolia and E. purpurea. Commercial ex-
tract was more potent, increasing GM-CFCs at 50mg/kg/d, but
limited, as a higher dose reversed to baseline. USDA E. angustifo-
lia PI 649026 activity thresholdwas 100mg/kg/d and yielded a 3-
fold increase in GM-CFCs at the highest dose, 200mg/kg/d, while
E. purpurea PI 649040 extract plateaued at a 2-fold increase. Echi-
nacea angustifolia PI 649029 was inactive. These results suggest
that the myelostimulatory constituent is not species-specific
and varies within species as evidenced by the very different ef-
fects of two E. angustifolia accessions. Active constituent is
shared between authentic USDA-derived material and the com-
mercial preparation; however, activity of the latter may be lim-
ited by a non-plant substance interfering at a higher dose.
Qualitative assessment of alkylamides in commercial Echinacea
ethanolic extract was aided by 13C NMR using APT as shown in
l" Fig. 1. Signals in the 60–80 ppm region indicate the presence of
acetylenic quaternary and methine carbons of Echinacea alkyl-
amides. It should be noted that use of τ = 5ms displays quaternary
and methylene carbons up, and methine, including acetylenes,
and methyl carbons down. The expected less intense downfield
quaternary signals from the amide carbons at 165–176 ppm rela-
tive to the acetylenic carbons are due to decreased sensitivity be-
causeof their longer relaxation timewith respect to the1 secdelay
time used in this experiment. The proton NMR spectrum of etha-
nolic extract is shown in l" Fig. 2A. Signals within δ = 3.00–5.00
indicate nitrogenated, acetylenic, oxygenated, and some olefinic
protons. Signals within δ = 6.00–7.50 represent some olefinic and
the aromatic protons of phenylpropanoids, including CADs.
The 1H NMR spectrum of the aqueous extract (Fig. 1S; see Sup-
porting Information) exhibits oxygenated polysaccharide pro-
tons at δ = 3.00–4.50 and δ = 5.00–5.50, peaks typical of anomeric
sugar protons [28]. Oxygenated polysaccharide sugar hydroxy-
methylene and methine carbons at 60–75 ppm dominate the
APT NMR (Fig. 2S). The MeOH‑CHCl3 wash was nearly pure fatty
acid as evident from its APT NMR spectrum (Fig. 3S) showing 11
carbons (δ 180.0, qC; 34.2, CH2; 31.7, CH2; 29.5–29.0, 5 CH2s;
24.8, CH2; 22.7, CH2; and 14.1, CH3). 1H NMR was consistent with
decanoic acid (δ 0.84, 3H, t, J = 7.3 Hz; 1.25, 12H, m; 1.58, 2H, m;
2.29, 2H, t, J = 7.3 Hz; 8.94, 1H, brs). MS analysis showed a 4:1
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mixture of decanoic acid [170.96, (M − H)−, C10H19O2] and nona-
noic acid [156.97, (M − H)−, C9H17O2].
NMR profiles of the ethanolic extract of the commercial prepara-
tion were compared to those from aerial parts of defined acces-
sions obtained from the USDA to validate the source of the com-
mercial material. 1H NMR spectra for all USDA material contain
aromatic signals around 7.00 ppm, characteristic for caffeic acid
and other phenylpropanoid derivatives (l" Fig. 2B–D). For PI
649040, the spin-spin coupling of the E-oriented olefinic α,β-un-
saturated protons (J = 16Hz) was observed. The δ = 3.00–5.00 re-
gion indicates a complex pattern of several nitrogenated, oxygen-
ated, olefinic, and acetylenic protons. APT NMR spectra of the US-
DA accessions (l" Fig. 3A–C) show similar upward-oriented qua-
ternary and downward-oriented methine acetylenic carbons res-
onating at 60–80 ppm for all three Echinacea accessions. Spectra
of commercial ethanolic extract (l" Figs. 1 and 2A) were qual-
itatively similar to those fromUSDA accessions, indicating that al-
kylamides and CADs were major chemical classes of extracts
from both commercial and authentic plant sources. However,
the commercial extract exhibited more upfield signals character-
istic of alkane protons (δ = 0.50–1.50) and methylene carbons
(20–35 ppm).
Shown inl" Figs. 4 and 5 are HPTLC patterns of 75% ethanolic ex-
tracts using polar and apolar mobile systems. Phenolic acid
standards cichoric acid, caftaric acid, and echinacoside (l" Fig. 4)
were cochromatographed with polar development. Caftaric acid
(Rf = 0.17) migratedwith a major band of extracts from E. purpur-
ea and a faint band of E. angustifolia. Cichoric acid (Rf = 0.71) was
Fig. 2 1H NMR spectra (400MHz, in DMSO‑d6) of
75% ethanol extracts of aerial parts of a commercial
E. purpurea (A), two accessions of E. angustifolia (B
and D) and one accession of E. purpurea (C) ob-
tained from the USDA North Central Regional Plant
Introduction Station. DMSO signals are evident at
2.50 ppm. Insert in C shows expanded δ = 6.0–
7.30 ppm region to illustrate spin-spin coupling.
Fig. 1 APT spectrum of 75% ethanolic extract of
aerial parts of a commercial E. purpurea in DMSO-d6
at 100MHz. The region circled in the top spectra is
expanded below. The region within the square cor-
responds to amide carbon. DMSO signal is evident
at 39.5 ppm.
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predominant in both lots of commercial E. purpurea and E. pur-
purea PI 649040. No distinct bands in the ethanolic extracts of
aerial parts of any Echinacea sources could be assigned to echina-
coside (Rf = 0.08). Unidentified phenolic components with
Rf = 0.82 and 0.27 were more abundant in both E. angustifolia
sources than in E. purpurea extracts, while another with
Rf = 0.38 was unique to E. angustifolia. Greater abundance of
cichoric and caftaric acids in E. purpurea and of components with
Rf 0.82, 0.38, and 0.27 in E. angustifolia authenticated the labeling
of the commercial material as E. purpurea.
TLC profiles of ethanolic extracts with apolar solvents exhibited
band E (l" Fig. 5, Rf = 0.52) common to all sources that comigrated
with β-sitosterol. Bands D, F, and G with Rf = 0.48, 0.65, and 0.71,
respectively, were evident in extracts from the USDA accessions
(lanes 1–3). Band C (Rf = 0.41)was aminor constituent of commer-
cial preparations. Band A (Rf = 0.23) was unique to E. angustifolia,
being most evident in PI 649029. Band B (Rf = 0.33) was observed
in E. angustifolia and commercial E. purpurea. Isolation of bands A
and B by preparative HPTLC and determination of parent-ion
mass byMS gave [M + H] + values of 230.2 and 248.2, respectively.
Mass of band A constituent and species-specificity suggest that it
is undeca-2Z,4E-diene-8,10-diynoic acid isobutyl amide, which
has been previously noted in E. angustifolia, but not E. purpurea,
flowers [31]. Mass of 248.2 and Rf relative to β-sitosterol are con-
sistent with identification of band B as 2E,4E,8Z,10E/Z-dodecate-
traenoic acid isobutyl amides [32,33]. Band H (Rf = 0.74) was
present only in commercial extracts and comigrated with the
major band of the MeOH‑CHCl3 wash, which had been shown by
NMR and MS to be nonanoic and decanoic acids. Detection of
these medium-chain fatty acids uniquely in the commercial ex-
tract was consistent with their NMR fingerprints suggesting sat-
urated alkane constituents derived from non-plant material
(l" Figs. 1 and 2A). We suspect that medium-chain triglyceride
additive to the commercial product, which is marketed as a food
additive with saturated C9 and C10 esters [26], hydrolyzed during
extraction and resulting fatty acids partitioned in the 75% etha-
nol phase.
Our initial objective was to determine whether Echinacea pre-
treatment would counter toxicity of MNX, a nitro-reduced prod-
uct of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), whose mye-
losuppression we had previously determined required 14 d for
Fig. 3 APT spectra of 75% ethanolic extracts (100 Hz in DMSO‑d6) of aerial
parts of one accession of E. purpurea (A) and two accessions of E. angustifolia
(B and C) obtained from the USDA North Central Regional Plant Introduction
Station. DMSO signals are evident at 39.5 ppm.
Fig. 4 HPTLC of 75% ethanolic extracts developed with a polar mobile
phase. Extracts from USDA E. angustifolia accessions PI 649029 and PI
649026, E. purpurea PI 649040, and 2 lots of commercial E. purpurea were
chromatographed. Standards are cichoric acid, caftaric acid, and echinaco-
side. Chromatograms were developed with EtOAc-acetone-formic acid-
water (15 :9 :1 :1). Origin and mobile phase front are indicated by an arrow
and arrowhead, respectively. Diphenylborinic acid aminoethylester spray
reagent and UV light, λ366 nm, were used for visualization.
Fig. 5 HPTLC of 75% ethanolic extracts developed with an apolar mobile
phase. Extracts of E. angustifolia 649029 and 649026, E. purpurea 649040
(lanes 1,2, and 3, resp.), and 2 lots of commercial E. purpureawere chroma-
tographed (lanes 4, 5). MeOH‑CH3Cl wash is in lane 6. Chromatogramswere
developed with toluene-EtOAc-cyclohexane-formic acid (24 :6 :3 :0.9).
β-sitosterol (band E, Rf 0.52) and C9-C10 fatty acids (band H) are indicated
by arrows and arrowheads, respectively. p-Anisaldehyde-sulfuric acid was
used for visualization.
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expression [34]. Hence, our early studies assessed the effects of
various Echinacea fractions 14 d after the last of 7 daily doses. It
was noted in these studies that pretreatment of ethanolic extract
of commercial Echinacea (50mg dried extract/kg/d), indepen-
dent of administration of myelotoxicant, increased GM-CFCs by
50% after the 14 d lag (Fig. 4S). We also tested for myelostimula-
tory activity of aqueous extract of the commercial material and
MeOH‑CHCl3 wash of the aqueous extract using the 14-d lag pro-
tocol. Both of these fractions, at doses derived from the amount of
starting material that yielded 50mg/kg dose of active ethanolic
extract, were without effect (Fig. 4S).
Myelostimulation by ethanolic extract of commercial Echinacea
evaluated 24 h after 7 daily doses (50mg/kg/d) was increased to
70% over vehicle (l" Fig. 6A). However, a higher dose (100mg/kg)
of this same extract yielded GM-CFCs similar to vehicle control.
For all USDA accessions at 50mg/kg/d, GM-CFCs were not in-
creased to statistical significance. However, higher doses of PI
649026 and PI 649040 caused a significant increase, with E. an-
gustifolia PI 649026 exhibiting the greatest activity at 3 times
GM-CFCs of vehicle at 200mg/kg/d. Echinacea purpurea PI
649040 also was active and plateaued at twice that of the vehicle
at 200mg/kg (l" Fig. 6A).
The ethanolic (50mg/kg) and aqueous extracts, andMeOH‑CHCl3
wash of commercial E. purpureawere without any effect on total
bone marrow cellularity. However, a higher dose (100mg/kg/d)
of commercial ethanolic extract significantly decreased the bone
marrow cell number (l" Fig. 6B). In contrast, ethanolic extracts of
USDA accessions did not affect bone marrow cellularity at any
dose, including a high dose (200mg/kg/d) (l" Fig. 6B). None of
the extracts at any dose affected body weight gain over the 7-
day treatment (mean ± SEM= 6.4 ± 1.4 g, n = 54). One rat of four
treated with 100mg/kg/d of ethanolic extract of commercial
Echinacea died on trial, while no lethality occurred with any dose
of extracts from the USDA accessions. These observations support
the notion that toxicity of the commercial extract at a higher dose
may have limited its myelostimulatory activity.
Results from this study are collectively summarized in l" Table 1.
In summary, our analytical work identified alkylamides and
CADs in Echinaceamyelostimulatory ethanolic extracts, but pres-
ence of the same in an inactive E. angustifolia extract precluded
assignment of activity to these chemical classes in general. No
identified entity correlatedwithmyelostimulatory activity across
Fig. 6 Effects of 75% ethanolic extract of commercial E. purpurea and cul-
tivars of E. angustifolia 649029 and 649026 and E. purpurea 649040 on fe-
mur GM-CFCs (A) and total bone marrow cells (B) of rats treated with 50,
100, and 200mg/kg/d. Rats received 7 daily doses of extract, and bone
marrow cells were processed 24 h after the last dose. Means ± SEM for n = 4
rats are shown. Means that differed from vehicle control (0mg/kg) by a
statistically significant amount are indicated by * p < 0.05 and ** p < 0.01.
Table 1 Analytical chemistry results and relative myeloproliferative activity of fractions from various Echinacea sources.
Chemistry
Source Fraction 1H NMR APT HPTLC Bioactivitya
Polar Apolar
Commercial
E. purpurea
75% Ethanolic CADs, Alkanes Alkylamides, Alkanes Cichoric,
Caftaric acids
β-Sitosterol, Decanoic, Nonanoic
acids, C12:4N iBub
1
E. purpurea
PI 649040
75% Ethanolic CADs Alkylamides Cichoric,
Caftaric acids
β-Sitosterol, 2
E. angustifolia
PI 649026
75% Ethanolic CADs Alkylamides Rf 0.82, 0.38
and 0.27c
β-Sitosterol,
C12:4N iBu
C11:2 :2N iBud
3
E. angustifolia
PI 649029
75% Ethanolic CADs Alkylamides Rf 0.82, 0.38
and 0.27
β-Sitosterol,
C12:4N iBu
C11:2 :2N iBu
0
Commercial
E. purpurea
MeOH‑CHCl3 Decanoic acid C11, Fatty acid nd β-Sitosterol, Decanoic,
Nonanoic acids (4 :1)e
0
Commercial
E. purpurea
Aqueous PS, CADs PS nd nd 0
a Myeloproliferative activity ranked from lowest (1) to highest (3) or as absent (0); b C12:4N iBu = 2E,4E,8Z,10E/Z-dodecatetraenoic acid isobutyl amides; c Mobility of bands of
unknown identity; d C11 :2 :2N iBu = undeca-2Z,4E-diene-8,10-diynoic acid isobutyl amide; e Identities and ratio confirmed by MS
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the various preparations. Hence, our study has identified a bio-
logical activity that is consistent with Echinacea immunostimula-
tion, but more detailed chemical analysis, fractionation, and opti-
mization of efficacy are required to identify responsible constitu-
ent(s).
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